What happens when weight-loss jabs are stopped?

Weight-loss injections, known as GLP-1s, have helped many shed pounds in ways traditional diets could not. But as use becomes more common, questions about what happens when people stop the medication have moved from clinical debate to lived experience. Two women in the United Kingdom—Tanya Hall and Ellen Ogley—describe starkly different paths after tapering or stopping their GLP-1 treatments, illustrating both the potential for lasting change and the challenges that can arise when the drugs are no longer in the bloodstream.

Tanya Hall, a sales manager for a large fitness company, began taking Wegovy after years of being overweight and feeling sidelined in her industry. She recalls an initial period of disruption: hair shedding, sleep problems, nausea, and headaches, symptoms she attributes to rapid weight loss and the body adjusting to a new regime. “My hair was falling out in clumps,” she says, describing the early months when she began using the injections. Yet she also notes meaningful weight loss—about three and a half stone in the first several months—followed by a longer arc of transformation. Over more than 18 months, she has shed about six stone (38 kilograms) and, for a time, grew accustomed to the sharper attention and perceived increased respect that accompanied her slimmer profile. But with that change came a growing dependence on the medication as a tool to regulate her body and appetite.

Nevertheless, Tanya has repeatedly attempted to stop Wegovy. Each time she halts the injections, she says, hunger returns with unusual intensity. “It’s like a switch that goes on and you’re instantly starving,” she recounts, describing a relapse that can feel immediate and overwhelming. The dilemma for Tanya is not only the physical sense of impending hunger but the psychological pull toward old eating patterns she associates with comfort and control. After trying to come off the drug several times, she has learned to anchor her decision in a careful cost-benefit calculus: the drug helps with weight management and self-esteem, but it also carries side effects and long-term uncertainties. For now, she remains on Wegovy and says she’s reached a weight she is comfortable with, despite the ongoing fear of regression.

The broader medical context echoes this tension. Stopping GLP-1s can feel like a sudden transition from a leveled playing field to a chaotic surge of appetite and cravings. A general practitioner who works with weight-management patients describes the moment of stopping as potentially catastrophic. “Stopping weight loss drugs can feel like jumping off a cliff,” says Dr Hussain Al-Zubaidi, a lifestyle GP. He notes that some patients who discontinue at the highest dose after reaching a target weight experience a rapid rebound, with the hunger returning as if a force had been reactivated. In early follow-up studies and clinical experience, he adds, a substantial share of lost weight tends to return within one to three years—roughly six-tenths to four-fifths of the weight can come back for many patients. The implication for Tanya and others is clear: the long-term path after stopping is highly individualized and often requires substantial ongoing support to maintain progress.

Tanya’s counterpart in the BBC report, Ellen Ogley, faced a different trajectory. Ellen started on Mounjaro after reaching a critical health point that made an intervention essential, describing herself as an emotional binge eater who used food to cope with happiness or sadness alike. She says the injections “turned off” that compulsion, enabling her to adopt a healthier reading of nutrition and a more active lifestyle. Ellen lost about 22 kilograms (3 st 7 lb) during a 16-week course, tapering off the drug over six weeks as she began to restructure her relationship with food. Her story highlights a potential upside of GLP-1s: improved self-control and the space to build sustainable habits, such as reading up on nutrition and engaging in regular exercise. Yet the moment she stopped the treatment, Ellen encountered renewed challenges. She reports that weight creep resumed, a development she says “messed my head up a little bit,” underscoring the fragility of progress without a supportive framework and ongoing lifestyle changes. She emphasizes that the right support is crucial in the transition away from pharmacologic weight management—and that without it, many patients risk returning to old patterns.

The contrast in Tanya’s and Ellen’s experiences points to a broader concern about how to sustain weight loss after GLP-1 therapy ends. Dr Al-Zubaidi notes that as patients approach the end of their treatment, there is often a window of time during which momentum—created by medical support, behavioral changes, and environmental conditions—needs to be converted into a lasting strategy. He describes the post-treatment phase as one in which many individuals are at risk if they lack a concrete exit plan. This is particularly true for patients who self-fund therapies, as access to structured support programs can be uneven. He emphasizes that the social and physical environment—such as access to healthy foods, safe options for physical activity, and sustained medical follow-up—plays a critical role in whether the weight remains off after treatment ends.

The UK’s health regulator has signaled a cautious, structured path for stopping GLP-1 therapy. The National Institute for Health and Care Excellence (Nice) recommends that patients receive at least a year of ongoing advice and a tailored action plan after stopping treatment to help them apply practical changes to their lifestyle and maintain health. This guidance aims to address the transition from clinical weight loss to everyday life, with or without pharmacological help. However, such sustained post-treatment support is not guaranteed for those who pay privately for therapy. For Tanya and Ellen, who funded their treatment themselves, gaps in post-treatment care may affect both outcomes and the long-term sustainability of weight loss.

As the BBC report notes, the companies behind these medications have underscored the medical context of GLP-1 therapy. Novo Nordisk, the maker of Wegovy, says that treatment decisions should be made in collaboration with a healthcare provider and that side effects should be considered within that decision. Eli Lilly, the maker of Mounjaro, similarly emphasizes patient safety as a priority and describes ongoing monitoring, evaluation, and reporting to regulators and prescribers. These statements reflect the clinical intent behind GLP-1 therapies: to offer effective weight management while ensuring patient safety through professional oversight.

For Tanya, the decision remains whether to stay on medication or attempt another taper with broader supports in place. She says she is at a weight she feels comfortable with and has learned to live with the realities of long-term medication use, including the potential for side effects. Ellen’s experience suggests a more complicated, but potentially hopeful, path: with the right behavioral supports and access to resources, the weight regained after stopping can be managed. Yet she also warns that stopping without adequate support can destabilize progress and complicate mental well-being.

Whatever the path, health professionals stress that weight loss and maintenance after GLP-1 therapy is not solely a pharmacological issue. Obesity is not a GLP-1 deficiency, says Dr Al-Zubaidi. Rather, it reflects a complex interplay of biology, psychology, and environment. The risk of relapse is real, and the long-term trajectory will depend on the combination of ongoing medical guidance, psychosocial support, nutrition education, and structural changes in the surrounding environment that promote health. The question remains whether healthcare systems, therapists, insurers, and clinicians can collaborate effectively to provide a continuum of care that helps patients maintain progress after GLP-1 therapy ends.

In the meantime, Tanya’s stance is pragmatic: she remains on Wegovy and is wary of stopping, balancing the weight loss benefits against the side effects. Ellen’s experience, by contrast, underscores the potential for a life after pharmacologic weight management that is sustainable, provided there is a robust plan and support network in place. Each story reflects a different aspect of a broader public health question: can modern weight-loss therapies deliver lasting change if the medical and social supports do not evolve in tandem with their use?

For the public, the takeaway is nuanced. GLP-1 therapies can produce meaningful weight loss and improvements in well-being, but stopping them is rarely a simple, predictable event. The post-treatment path—shaped by whether individuals can adapt their eating behaviours, sustain healthier routines, and secure ongoing medical and social support—appears to determine whether weight loss endures over the long term. As more people use these medications, society will need to contend not only with their efficacy during treatment but with the systems required to sustain health after treatment ends.

IMAGE:

The implication for patients is clear: stopping GLP-1 treatment is not a one-size-fits-all decision, and it benefits from careful planning, medical supervision, and a robust post-treatment lifestyle strategy. For Tanya, that means continuing a drug-assisted approach with a careful eye on side effects and personal tolerance. For Ellen, it means pursuing a path that couples medical guidance with behavioral changes that make weight maintenance possible without continuous pharmacologic support. And for the health system at large, it means expanding access to ongoing, personalized care for all who use these therapies, regardless of whether they pay privately or through public channels, ensuring that the momentum gained during treatment can translate into lasting health gains after the injections stop.